<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37301412</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of allergy and clinical immunology</Title><ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Histamine-releasing factor in severe asthma and rhinovirus-associated asthma exacerbation.</ArticleTitle><Pagination><StartPage>633</StartPage><EndPage>640.e4</EndPage><MedlinePgn>633-640.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2023.04.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-6749(23)00707-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Histamine-releasing factor (HRF) is implicated in allergic diseases. We previously showed its pathogenic role in murine models of asthma.</AbstractText><AbstractText Label="OBJECTIVE">We aim to present data analysis from 3 separate human samples (sera samples from asthmatic patients, nasal washings from rhinovirus [RV]-infected individuals, and sera samples from patients with RV-induced asthma exacerbation) and 1 mouse sample to investigate correlates of HRF function in asthma and virus-induced asthma exacerbations.</AbstractText><AbstractText Label="METHODS">Total IgE and HRF-reactive IgE/IgG as well as HRF in sera from patients with mild/moderate asthma or severe asthma (SA) and healthy controls (HCs) were quantified by ELISA. HRF secretion in culture media from RV-infected adenovirus-12 SV40 hybrid virus transformed human bronchial epithelial cells and in nasal washings from experimentally RV-infected subjects was analyzed by Western blotting. HRF-reactive IgE/IgG levels in longitudinal serum samples from patients with asthma exacerbations were also quantified.</AbstractText><AbstractText Label="RESULTS">HRF-reactive IgE and total IgE levels were higher in patients with SA than in HCs, whereas HRF-reactive IgG (and IgG<sub>1</sub>) level was lower in asthmatic patients versus HCs. In comparison with HRF-reactive IgE<sup>low</sup> asthmatic patients, HRF-reactive IgE<sup>high</sup> asthmatic patients had a tendency to release more tryptase and prostaglandin D<sub>2</sub> on anti-IgE stimulation of bronchoalveolar lavage cells. RV infection induced HRF secretion from adenovirus-12 SV40 hybrid virus transformed bronchial epithelial cells, and intranasal RV infection of human subjects induced increased HRF secretion in nasal washes. Asthmatic patients had higher levels of HRF-reactive IgE at the time of asthma exacerbations associated with RV infection, compared with those after the resolution. This phenomenon was not seen in asthma exacerbations without viral infections.</AbstractText><AbstractText Label="CONCLUSIONS">HRF-reactive IgE is higher in patients with SA. RV infection induces HRF secretion from respiratory epithelial cells both in vitro and in vivo. These results suggest the role of HRF in asthma severity and RV-induced asthma exacerbation.</AbstractText><CopyrightInformation>Copyright © 2023 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takazawa</LastName><ForeName>Ikuo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fajt</LastName><ForeName>Merritt L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasakura</LastName><ForeName>Kazumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Julienne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantor</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Children's Hospital, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phipatanakul</LastName><ForeName>Wanda</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Immunology, Children's Hospital, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heymann</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Asthma and Allergic Diseases Center, University of Virginia, Charlottsville, Va; Division of Pediatric Respiratory Medicine, University of Virginia, Charlottsville, Va.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedict</LastName><ForeName>Chris A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Benedict Laboratory, Center for Autoimmunity and Inflammation and Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Allergic Diseases, La Jolla Institute for Immunology, La Jolla, Calif. Electronic address: toshi@lji.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI101423</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI139749</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL124283</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 HL098102</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD040128</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI146042</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI101423</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001102</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI106822</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI073964</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL069174</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD047349</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI125179</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol</MedlineTA><NlmUniqueID>1275002</NlmUniqueID><ISSNLinking>0091-6749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>820484N8I3</RegistryNumber><NameOfSubstance UI="D006632">Histamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>37341-29-0</RegistryNumber><NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010850" MajorTopicYN="Y">Picornaviridae Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">HRF</Keyword><Keyword MajorTopicYN="N">IgE</Keyword><Keyword MajorTopicYN="N">IgG</Keyword><Keyword MajorTopicYN="N">asthma exacerbation</Keyword><Keyword MajorTopicYN="N">rhinovirus</Keyword></KeywordList><CoiStatement>Disclosure of potential conflict of interest: T.K. has consulted for Escient Pharma and HuBit Genomix on projects totally unrelated to this study. Otherwise, we declare that no authors have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>11</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37301412</ArticleId><ArticleId IdType="mid">NIHMS1909228</ArticleId><ArticleId IdType="pmc">PMC10917146</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2023.04.021</ArticleId><ArticleId IdType="pii">S0091-6749(23)00707-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Telerman A, Amson R. TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease: Springer Nature; 2017.</Citation></Reference><Reference><Citation>Kawakami Y, Kasakura K, Kawakami T. Histamine-Releasing Factor, a New Therapeutic Target in Allergic Diseases. Cells. 2019;8(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6952944</ArticleId><ArticleId IdType="pubmed">31779161</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald SM. Histamine releasing factors and IgE heterogeneity. 4 ed. Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. St Louis: Mosby-Year Book Incorporated; 1993.</Citation></Reference><Reference><Citation>Kashiwakura J, Ando T, Matsumoto K, Kimura M, Kitaura J, Matho MH, et al. Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy. The Journal of clinical investigation. 2012;122(1):218–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248297</ArticleId><ArticleId IdType="pubmed">22133880</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore KA, Kashiwakura JI, McDonnell JM, Gould HJ, Kawakami T, Sutton BJ, et al. Crystal structures of murine and human Histamine-Releasing Factor (HRF/TCTP) and a model for HRF dimerisation in mast cell activation. Mol Immunol. 2018;93:216–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5966295</ArticleId><ArticleId IdType="pubmed">29216544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasakura K, Kawakami Y, Jacquet A, Kawakami T. Histamine-Releasing Factor Is a Novel Alarmin Induced by House Dust Mite Allergen, Cytokines, and Cell Death. J Immunol. 2022;209(10):1851–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9643630</ArticleId><ArticleId IdType="pubmed">36426937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol. 2017;140(4):895–906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172811</ArticleId><ArticleId IdType="pubmed">28987219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhail I, Grayson MH. Asthma and viral infections: An intricate relationship. Ann Allergy Asthma Immunol. 2019;123(4):352–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111180</ArticleId><ArticleId IdType="pubmed">31276807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gern JE. How rhinovirus infections cause exacerbations of asthma. Clin Exp Allergy. 2015;45(1):32–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25270551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol. 2010;125(6):1178–87; quiz 88–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172767</ArticleId><ArticleId IdType="pubmed">20513517</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WW, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med. 2011;183(3):299–309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056228</ArticleId><ArticleId IdType="pubmed">20813890</ArticleId></ArticleIdList></Reference><Reference><Citation>Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699–705.</Citation><ArticleIdList><ArticleId IdType="pubmed">12037149</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002;57(8):677–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1746401</ArticleId><ArticleId IdType="pubmed">12149526</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742757</ArticleId><ArticleId IdType="pubmed">19483109</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman MC, Lai Y, Nolin JD, Long S, Chen CC, Piliponsky AM, et al. Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. J Clin Invest. 2019;129(11):4979–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819127</ArticleId><ArticleId IdType="pubmed">31437129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Message SD, Qiu Y, Mallia P, Kebadze T, Contoli M, et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest. 2014;145(6):1219–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4042510</ArticleId><ArticleId IdType="pubmed">24457412</ArticleId></ArticleIdList></Reference><Reference><Citation>Akoto C, Davies DE, Swindle EJ. Mast cells are permissive for rhinovirus replication: potential implications for asthma exacerbations. Clin Exp Allergy. 2017;47(3):351–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5396281</ArticleId><ArticleId IdType="pubmed">28008678</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093964</ArticleId><ArticleId IdType="pubmed">21410369</ArticleId></ArticleIdList></Reference><Reference><Citation>Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ J. 2014;7(1):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114087</ArticleId><ArticleId IdType="pubmed">25097719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantor DB, McDonald MC, Stenquist N, Schultz BJ, Smallwood CD, Nelson KA, et al. Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation. American Journal of Respiratory and Critical Care Medicine. 2016;194(12):1552–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215034</ArticleId><ArticleId IdType="pubmed">27976938</ArticleId></ArticleIdList></Reference><Reference><Citation>Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. Journal of Allergy and Clinical Immunology. 2015;136(6):1476–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4679705</ArticleId><ArticleId IdType="pubmed">26518090</ArticleId></ArticleIdList></Reference><Reference><Citation>Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000;162(6):2341–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11112161</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837934</ArticleId><ArticleId IdType="pubmed">17291857</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore WC, Evans MD, Bleecker ER, Busse WW, Calhoun WJ, Castro M, et al. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol. 2011;128(2):328–36 e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149754</ArticleId><ArticleId IdType="pubmed">21496892</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131(6):1504–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889167</ArticleId><ArticleId IdType="pubmed">23506843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr., Gern J, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129(3 Suppl):S34–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595577</ArticleId><ArticleId IdType="pubmed">22386508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6 Pt 2):1–120.</Citation><ArticleIdList><ArticleId IdType="pubmed">742764</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymann PW, Platts-Mills TAE, Woodfolk JA, Borish L, Murphy DD, Carper HT, et al. Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. J Allergy Clin Immunol. 2020;146(3):545–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733370</ArticleId><ArticleId IdType="pubmed">32018030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando T, Kashiwakura JI, Itoh-Nagato N, Yamashita H, Baba M, Kawakami Y, et al. Histamine-releasing factor enhances food allergy. J Clin Invest. 2017;127(12):4541–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5707161</ArticleId><ArticleId IdType="pubmed">29130935</ArticleId></ArticleIdList></Reference><Reference><Citation>Picarda G, Ghosh R, McDonald B, Verma S, Thiault N, El Morabiti R, et al. Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses. J Virol. 2019;93(16).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675903</ArticleId><ArticleId IdType="pubmed">31142671</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharajiya N, Vaidya SV, Murai H, Cardenas V, Kurosky A, Boldogh I, et al. FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma. PLoS One. 2010;5(2):e9337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825267</ArticleId><ArticleId IdType="pubmed">20179765</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H, Dolpady J, Wabl M, Curotto de Lafaille MA, Lafaille JJ. Sequential class switching is required for the generation of high affinity IgE antibodies. J Exp Med. 2012;209(2):353–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280879</ArticleId><ArticleId IdType="pubmed">22249450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AK, Croft M. Rhinovirus Infection Promotes Eosinophilic Airway Inflammation after Prior Exposure to House Dust Mite Allergen. Immunohorizons. 2020;4(8):498–507.</Citation><ArticleIdList><ArticleId IdType="pubmed">32792363</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25457152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantor DB, Stenquist N, McDonald MC, Schultz BJ, Hauptman M, Smallwood CD, et al. Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. J Allergy Clin Immunol. 2016;138(5):1467–71 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099095</ArticleId><ArticleId IdType="pubmed">27474123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami T, Blank U. From IgE to Omalizumab. J Immunol. 2016;197(11):4187–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123831</ArticleId><ArticleId IdType="pubmed">27864548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>